Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner

被引:101
作者
Kajinami, K
Brousseau, ME
Ordovas, JM
Schaefer, EJ
机构
[1] Kanazawa Med Univ, Dept Cardiol, Uchinada, Ishikawa 9200293, Japan
[2] Tufts Univ, New England Med Ctr, Div Endocrinol Metab & Mol Biol, Lipid Res Lab, Boston, MA 02111 USA
[3] Tufts Univ, Human Nutr Res Ctr Aging, USDA, Lipid Metab Lab, Boston, MA 02111 USA
关键词
D O I
10.1016/j.amjcard.2004.01.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To test the hypothesis that variations in the multidrug resistance-1 gene influence the response to statin treatment, 2 prevalent polymorphisms (G2677T/A and C3435T) were examined in 344 hypercholesterolemic patients treated with atorvastatin (10 mg). The C3435T polymorphism was significantly, and independently associated with a smaller reduction in lowdensity lipoprotein cholesterol and with a larger increase in high-density lipoprotein cholesterol, relative to variant allele carriers, in a gender-specific manner. Also, haplotype determination combined with these polymorphisms identified a subgroup that showed a striking response to treatment, which was not defined by a single polymorphism. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:1046 / 1050
页数:5
相关论文
共 18 条
[1]  
Berge KE, 2002, J LIPID RES, V43, P486
[2]   HMG-CoA reductase inhibitors and P-glycoprotein modulation [J].
Bogman, K ;
Peyer, AK ;
Török, M ;
Küsters, E ;
Drewe, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (06) :1183-1192
[3]   New insights into the pharmacodynamic and pharmacokinetic properties of statins [J].
Corsini, A ;
Bellosta, S ;
Baetta, R ;
Fumagalli, R ;
Paoletti, R ;
Bernini, F .
PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) :413-428
[4]   Comparison of one-year efficacy and safety of Atorvastatin versus Lovastatin in primary hypercholesterolemia [J].
Davidson, M ;
McKenney, J ;
Stein, E ;
Schrott, H ;
BakkerArkema, R ;
Fayyad, R ;
Black, D .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (11) :1475-1481
[5]   Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].
Evans, WE ;
McLeod, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549
[6]   Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study [J].
Fellay, J ;
Marzolini, C ;
Meaden, ER ;
Back, DJ ;
Buclin, T ;
Chave, JP ;
Decosterd, LA ;
Furrer, H ;
Opravil, M ;
Pantaleo, G ;
Retelska, D ;
Ruiz, L ;
Schinkel, AH ;
Vernazza, P ;
Eap, CB ;
Telenti, A .
LANCET, 2002, 359 (9300) :30-36
[7]   The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans [J].
Fromm, MF .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (10) :1295-1310
[8]   Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase - Further experimental evidence for a multisite model [J].
Garrigos, M ;
Mir, LM ;
Orlowski, S .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 244 (02) :664-673
[9]   Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].
Hoffmeyer, S ;
Burk, O ;
von Richter, O ;
Arnold, HP ;
Brockmöller, J ;
Johne, A ;
Cascorbi, I ;
Gerloff, T ;
Roots, I ;
Eichelbaum, M ;
Brinkmann, U .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3473-3478
[10]  
Kalow W, 1998, PHARMACOGENETICS, V8, P283